Publications: 2021

Garcia-Prats, A. J., Svensson, E. M., Winckler, J., Draper, H. R., Fairlie, L., Van Der Laan, L. E., Masenya, M., Schaaf, H. S., Wiesner, L., Norman, J., Aarnoutse, R. E., Karlsson, M. O., Denti, P., & Hesseling, A. C. (2021). Pharmacokinetics and safety of high-dose rifampicin in children with TB: The Opti-Rif trial. Journal of Antimicrobial Chemotherapy, 76(12), 3237–3246. https://doi.org/10.1093/JAC/DKAB336

Gausi, K., Ignatius, E. H., Sun, X., Kim, S., Moran, L., Wiesner, L., Von Groote-Bidlingmaier, F., Hafner, R., Donahue, K., Vanker, N., Rosenkranz, S. L., Swindells, S., Diacon, A. H., Nuermberger, E. L., Dooley, K. E., & Denti, P. (2021). A semimechanistic model of the bactericidal activity of high-dose isoniazid against multidrug-resistant tuberculosis: Results from a randomized clinical trial. American Journal of Respiratory and Critical Care Medicine, 204(11), 1327–1335. https://doi.org/10.1164/RCCM.202103-0534OC

Anyorigiya, T. A., Castel, S., Mauff, K., Atuguba, F., Ogutu, B., Oduro, A., Dosoo, D., Asante, K. P., Owusu-Agyei, S., Dodoo, A., Hodgson, A., Binka, F., Workman, L. J., Allen, E. N., Denti, P., Wiesner, L., & Barnes, K. I. (2021). Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria. Malaria Journal, 20(1). https://doi.org/10.1186/S12936-020-03553-6

Wasmann, R. E., Svensson, E. M., Walker, A. S., Clements, M. N., & Denti, P. (2021). Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African children. British Journal of Clinical Pharmacology, 87(7), 2847–2854. https://doi.org/10.1111/BCP.14694

Sturkenboom, M. G. G., Märtson, A. G., Svensson, E. M., Sloan, D. J., Dooley, K. E., van den Elsen, S. H. J., Denti, P., Peloquin, C. A., Aarnoutse, R. E., & Alffenaar, J. W. C. (2021). Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. Clinical Pharmacokinetics, 60(6), 685–710. https://doi.org/10.1007/S40262-021-00997-0

Egbelowo, O., Sarathy, J. P., Gausi, K., Zimmerman, M. D., Wang, H., Wijnant, G. J., Kay, F., Gengenbacher, M., Van, N., Degefu, Y., Nacy, C., Aldridge, B. B., Carter, C. L., Denti, P., & Dartois, V. (2021). Pharmacokinetics and target attainment of SQ109 in plasma and human-like tuberculosis lesions in rabbits. Antimicrobial Agents and Chemotherapy, 65(9). https://doi.org/10.1128/AAC.00024-21

Ngwalero, P., Brust, J. C. M., van Beek, S. W., Wasserman, S., Maartens, G., Meintjes, G., Joubert, A., Norman, J., Castel, S., Gandhi, N. R., Denti, P., McIlleron, H., Svensson, E. M., & Wiesner, L. (2021). Relationship between plasma and intracellular concentrations of bedaquiline and its m2 metabolite in South African patients with rifampin-resistant tuberculosis. Antimicrobial Agents and Chemotherapy, 65(11). https://doi.org/10.1128/AAC.02399-20

Abdelwahab, M. T., Wasserman, S., Brust, J. C. M., Dheda, K., Wiesner, L., Gandhi, N. R., Warren, R. M., Sirgel, F. A., Meintjes, G., Maartens, G., & Denti, P. (2021). Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/AAC.01381-21

Gausi, K., Wiesner, L., Norman, J., Wallis, C. L., Onyango-Makumbi, C., Chipato, T., Haas, D. W., Browning, R., Chakhtoura, N., Montepiedra, G., Aaron, L., McCarthy, K., Bradford, S., Vhembo, T., Stranix-Chibanda, L., Masheto, G. R., Violari, A., Mmbaga, B. T., Aurpibul, L., … Denti, P. (2021). Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clinical Pharmacology and Therapeutics, 109(4), 1034–1044. https://doi.org/10.1002/cpt.2044

Abdelwahab, M. T., Court, R., Everitt, D., Diacon, A. H., Dawson, R., Svensson, E. M., Maartens, G., & Denti, P. (2021). The effect of Clofazimine Concentration on QT prolongation in patients treated for tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/AAC.02687-20

Court, R., Centner, C. M., Chirehwa, M., Wiesner, L., Denti, P., de Vries, N., Harding, J., Gumbo, T., Maartens, G., & McIlleron, H. (2021). Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. International Journal of Infectious Diseases, 105, 688–694. https://doi.org/10.1016/J.IJID.2021.03.001

Ignatius, E. H., Abdelwahab, M. T., Hendricks, B., Gupte, N., Narunsky, K., Wiesner, L., Barnes, G., Dawson, R., Dooley, K. E., Denti, P., Carstens, D., Smits, T., Whitlaw, C., & Truter, I. (2021). Pretomanid pharmacokinetics in the presence of rifamycins: Interim results from a randomized trial among patients with tuberculosis. Antimicrobial Agents and Chemotherapy, 65(2). https://doi.org/10.1128/AAC.01196-20

Chirehwa, M. T., Court, R., de Kock, M., Wiesner, L., de Vries, N., Harding, J., Gumbo, T., Maartens, G., Warren, R., Denti, P., & McIlleron, H. (2021). Effect of isoniazid intake on ethionamide pharmacokinetics and target attainment in multidrug-resistant tuberculosis patients. Antimicrobial Agents and Chemotherapy, 65(10). https://doi.org/10.1128/AAC.00278-21

Montanha, M. C., Fabrega, F., Howarth, A., Cottura, N., Kinvig, H., Bunglawala, F., Lloyd, A., Denti, P., Waitt, C., & Siccardi, M. (2021). Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. Clinical Pharmacokinetics. https://doi.org/10.1007/S40262-021-01067-1

Francis, J., Mngqibisa, R., McIlleron, H., Kendall, M. A., Wu, X., Dooley, K. E., Firnhaber, C., Godfrey, C., Cohn, S. E., & Denti, P. (2021). A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clinical Pharmacology and Therapeutics, 110(4), 1057–1065. https://doi.org/10.1002/CPT.2324